All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1346P"
1346P - Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
- Juergen Wolf (Cologne, Germany)
Abstract
Background
Capmatinib (Tabrecta®) is an orally bioavailable, highly potent and selective MET inhibitor (METi). Data from the GEOMETRY mono-1 study, a non-randomized, phase 2 trial of capmatinib in patients (pts) with MET exon 14 skipping mutation (METΔex14) metastatic NSCLC, demonstrated an objective response rate of 68% in treatment-naïve pts.
Methods
This retrospective cohort study examined the clinical characteristics, treatment patterns, and clinical outcomes of a cohort of real-world (RW) pts with METΔex14 NSCLC from the Flatiron Health-Foundation Medicine de-identified Clinico-genomic Database. RW progression-free survival (rwPFS) and overall survival (OS) of pts who received first-line chemotherapy and/or immune checkpoint inhibitor therapy in the metastatic setting were compared with RECIST-based PFS and OS of treatment-naive METΔex14 NSCLC pts who received capmatinib in the GEOMETRY mono-1 trial. An inverse odds weighting approach was used as a method of covariate balancing that estimated the Average Treatment effect on the Treated (ATT).
Results
Baseline demographics and clinical characteristics are in the table. Median (95% CI) PFS was 12.0 (5.5, 20.7) vs median rwPFS of 6.1 (3.4, 8.1) months for the trial and RW pts, respectively; following ATT weighting, median PFS was 12.0 (5.5, 20.7) vs median rwPFS of 6.2 (3.4, 9.1) months, respectively. Median (95% CI) OS was 20.8 (12.4, not reached [NR]) vs 14.8 (7.7, 26.2) months for the trial and RW pts respectively; following ATT weighting, median OS was 20.8 (12.4, NR) vs 20.0 (7.2, NR) months, respectively. A number of RW pts received METi after progression on first line (n=11, pre-weighting; n=8.8, after ATT-weighting) Results are n (%) unless otherwise stated.
Real-world patients GEOMETRY mono-1 (N = 28) 18 (64) 19 (46) 19.8 (67) 72.4 (7) 74 (8.5) 72 (8.2) 10 (36) 26 (63) 9.5 (32) Squamous cell carcinoma 2 (7) 2 (5) 2.2 (7) Adenocarcinoma 25 (89) 38 (93) 26.8 (91) Other 1(4) 1 (2) 0.4 (1) 3 (11) 10 (24) 2.3 (8) 0 7 (25) 9 (22) 7.3 (25) 1 21 (75) 32 (78) 22.1 (75) PD-L1 monotherapy - 6 (15) 2.2 (8) PD-L1 + chemotherapy - 9 (22) 5.5 (19) Platinum-doublet chemotherapy - 25 (61) 21.6 (73) Single-agent chemotherapy - 1 (2) 0.1 (0) Trial treatment 28 (100) - -
Conclusions
Based on this retrospective RW comparison, capmatinib confers longer PFS vs treatments available as first-line for advanced METΔex14 NSCLC, before and after matching for differences in baseline and clinical characteristics.
Clinical trial identification
NCT02414139.
Editorial acknowledgement
Martin Wallace, Novartis Pharma AG.
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceutical Corporation.
Disclosure
J. Wolf: Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Blueprint; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Chugai; Honoraria (self), Advisory/Consultancy: Ignyta; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Janssen; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Loxo; Honoraria (self), Advisory/Consultancy: Merck Sharp & Dohme; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Seattle Genetics. J.W. Neal: Honoraria (self): Research to Practice; Honoraria (self): MLI Peerview; Honoraria (self): Medscape; Honoraria (self): Biomedical Learning Institute; Honoraria (self): Prime Oncology; Honoraria (self): Rockpointe; Honoraria (self): CME Matters; Honoraria (self): MJH CME; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Jounce Therapeutics; Advisory/Consultancy: Takeda Pharmaceuticals; Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy: Calithera Biosciences; Advisory/Consultancy: Amgen; Advisory/Consultancy: Iovance Biotherapeutics; Research grant/Funding (institution): Genentech/Roch; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Exelixis; Research grant/Funding (institution): Nektar Therapeutics; Research grant/Funding (institution): Takeda Pharmaceuticals; Research grant/Funding (institution): Adaptimmune; Research grant/Funding (institution): GSK. A.S. Mansfield: Advisory/Consultancy: Trovagene; Advisory/Consultancy: Genentech; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: AbbVie; Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): Novartis. V. Doban, A. Joshi, E. de Jong, M. Giovannini: Full/Part-time employment: Novartis. H. Kanakamedala, W-H. Wu: Full/Part-time employment: Genesis Research. C.S. Baik: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Calgene Inc; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): Genentech Inc; Research grant/Funding (institution): Loxo Oncology; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Spectrum Pharmaceuticals; Research grant/Funding (institution): BluePrint Medicines; Research grant/Funding (institution): Daiichi Sankyo Inc; Research grant/Funding (institution): Rain Therapeutics; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): TP Therapeutics; Research grant/Funding (institution): Lilly Oncology.